1-4 of 4
Brian Gadbaw
Close
Sort by
Journal Articles

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study

Clinical Trials & Observations
Ali T. Taher, Zeynep Karakas, Elena Cassinerio, Noppadol Siritanaratkul, Antonis Kattamis, Aurelio Maggio, Stefano Rivella, Norbert Hollaender, Bruyère Mahuzier, Brian Gadbaw, Yesim Aydinok
Journal: Blood
Blood (2018) 131 (2): 263–265.
https://doi.org/10.1182/blood-2017-06-790121
Published: 2018
Includes: Supplemental data
Journal Articles

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Yesim Aydinok, MD, Zeynep Karakas, MD, Elena Cassinerio, MD, Noppadol Siritanaratkul, MD, Antonis Kattamis, MD, Aurelio Maggio, MD, Norbert Hollaender, PhD, Bruyère Mahuzier, Pharm D, Brian Gadbaw, MD, Ali T. Taher, MD PhD
Journal: Blood
Blood (2016) 128 (22): 852.
https://doi.org/10.1182/blood.V128.22.852.852
Published: 2016
Journal Articles

The Effect of Ruxolitinib on White Blood Cell Counts in Patients with Polycythemia Vera: Results from the RESPONSE Trial

Carole B. Miller, MD, Jean-Jacques Kiladjian, MD PhD, Martin Griesshammer, MD, Ahmad B. Naim, MD, William Sun, PhD, Brian Gadbaw, MD, Srdan Verstovsek, MD PhD, Alessandro M. Vannucchi
Journal: Blood
Blood (2015) 126 (23): 4070.
https://doi.org/10.1182/blood.V126.23.4070.4070
Published: 2015
Journal Articles

Continued Treatment with Ruxolitinib Provides Additional Hematocrit Control and Spleen Volume Responses in Patients with PV Treated in the RESPONSE Study

Jean-Jacques Kiladjian, MD PhD, Tamás Masszi, MD PhD, Mark M. Jones, MD, Brian Gadbaw, MD, Jingjin Li, PhD, Dany Habr, MD, Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2804.
https://doi.org/10.1182/blood.V126.23.2804.2804
Published: 2015